Etzer Darout
Stock Analyst at Barclays
(3.30)
# 1,047
Out of 5,044 analysts
132
Total ratings
43.81%
Success rate
4.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Overweight | $15 → $14 | $8.59 | +62.98% | 7 | Oct 22, 2025 | |
| SMMT Summit Therapeutics | Maintains: Underweight | $13 → $16 | $19.23 | -16.80% | 2 | Oct 21, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $35 → $58 | $30.13 | +92.50% | 2 | Oct 21, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $3.5 → $6 | $3.32 | +80.72% | 12 | Oct 21, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Underweight | $25 | $27.06 | -7.61% | 1 | Oct 13, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Overweight | $61 | $4.72 | +1,192.37% | 1 | Oct 13, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Overweight | $48 | $27.44 | +74.93% | 1 | Oct 13, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Overweight | $125 | $79.92 | +56.41% | 1 | Oct 13, 2025 | |
| CRVS Corvus Pharmaceuticals | Initiates: Overweight | $16 | $7.59 | +110.80% | 1 | Oct 13, 2025 | |
| ANAB AnaptysBio | Initiates: Overweight | $78 | $36.16 | +115.71% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $142 | $94.25 | +50.67% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $112 → $97 | $94.89 | +2.22% | 8 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $44 | $29.88 | +47.26% | 6 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $10 | $2.58 | +287.60% | 5 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $6 | $14.25 | -57.89% | 6 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $3 | $1.85 | +62.16% | 10 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $40 | $40.08 | -0.19% | 4 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $9.50 | +68.42% | 5 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $78.51 | -8.29% | 3 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $61.95 | -3.15% | 2 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $47 | $29.76 | +57.93% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $5.27 | +146.68% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $105.03 | +36.15% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $2.56 | +17.19% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $47.98 | +4.21% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $11.90 | +194.12% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $2.34 | +2,592.31% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.98 | +1,263.64% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $101.22 | +32.38% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $29.13 | +64.78% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $123.43 | -2.78% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.49 | +302.68% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $82.61 | -0.74% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.45 | +326.97% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $475.91 | -64.28% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $54.00 | - | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $70.51 | -46.11% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $2.39 | +2,075.73% | 1 | Mar 28, 2018 |
Terns Pharmaceuticals
Oct 22, 2025
Maintains: Overweight
Price Target: $15 → $14
Current: $8.59
Upside: +62.98%
Summit Therapeutics
Oct 21, 2025
Maintains: Underweight
Price Target: $13 → $16
Current: $19.23
Upside: -16.80%
RAPT Therapeutics
Oct 21, 2025
Maintains: Overweight
Price Target: $35 → $58
Current: $30.13
Upside: +92.50%
CytomX Therapeutics
Oct 21, 2025
Maintains: Overweight
Price Target: $3.5 → $6
Current: $3.32
Upside: +80.72%
Celldex Therapeutics
Oct 13, 2025
Initiates: Underweight
Price Target: $25
Current: $27.06
Upside: -7.61%
Tvardi Therapeutics
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $4.72
Upside: +1,192.37%
Oruka Therapeutics
Oct 13, 2025
Initiates: Overweight
Price Target: $48
Current: $27.44
Upside: +74.93%
Monopar Therapeutics
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $79.92
Upside: +56.41%
Corvus Pharmaceuticals
Oct 13, 2025
Initiates: Overweight
Price Target: $16
Current: $7.59
Upside: +110.80%
AnaptysBio
Oct 13, 2025
Initiates: Overweight
Price Target: $78
Current: $36.16
Upside: +115.71%
Oct 13, 2025
Initiates: Overweight
Price Target: $142
Current: $94.25
Upside: +50.67%
Sep 30, 2025
Downgrades: Equal-Weight
Price Target: $112 → $97
Current: $94.89
Upside: +2.22%
Sep 24, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $29.88
Upside: +47.26%
Sep 23, 2025
Maintains: Overweight
Price Target: $8 → $10
Current: $2.58
Upside: +287.60%
Sep 17, 2025
Assumes: Underweight
Price Target: $6
Current: $14.25
Upside: -57.89%
Sep 17, 2025
Assumes: Overweight
Price Target: $3
Current: $1.85
Upside: +62.16%
Sep 17, 2025
Initiates: Equal-Weight
Price Target: $40
Current: $40.08
Upside: -0.19%
Sep 17, 2025
Assumes: Overweight
Price Target: $16
Current: $9.50
Upside: +68.42%
Sep 17, 2025
Initiates: Overweight
Price Target: $72
Current: $78.51
Upside: -8.29%
Sep 17, 2025
Initiates: Overweight
Price Target: $60
Current: $61.95
Upside: -3.15%
Sep 17, 2025
Initiates: Overweight
Price Target: $47
Current: $29.76
Upside: +57.93%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $5.27
Upside: +146.68%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $105.03
Upside: +36.15%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $2.56
Upside: +17.19%
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $47.98
Upside: +4.21%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $11.90
Upside: +194.12%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $2.34
Upside: +2,592.31%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.98
Upside: +1,263.64%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $101.22
Upside: +32.38%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $29.13
Upside: +64.78%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $123.43
Upside: -2.78%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.49
Upside: +302.68%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $82.61
Upside: -0.74%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.45
Upside: +326.97%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $475.91
Upside: -64.28%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $54.00
Upside: -
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $70.51
Upside: -46.11%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $2.39
Upside: +2,075.73%